Early trial tests new obesity Drug's absorption
NCT ID NCT07226778
Summary
This early-stage study aims to understand how the body absorbs and processes an experimental drug called maridebart cafraglutide (AMG 133) for weight management. Researchers will compare two different injection forms of the drug in 348 adults living with overweight or obesity. The main goal is to measure drug levels in the blood and track safety, not to test weight loss effectiveness at this phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801-2658, United States
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4989, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
-
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, 53704-2526, United States
Conditions
Explore the condition pages connected to this study.